Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells $97,080.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $16.18, for a total value of $97,080.00. Following the sale, the general counsel now owns 105,386 shares in the company, valued at $1,705,145.48. The trade was a 5.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock opened at $16.63 on Friday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock’s fifty day moving average is $16.71 and its two-hundred day moving average is $15.83. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The company has a market capitalization of $2.19 billion, a PE ratio of -10.87 and a beta of 1.53.

Analyst Ratings Changes

A number of research analysts have weighed in on CNTA shares. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $25.83.

Institutional Trading of Centessa Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in Centessa Pharmaceuticals during the 4th quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC raised its stake in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC boosted its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $162,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.